Cargando…
COVID-19, steroids, and mucormycosis: What an ophthalmologist should know
Autores principales: | Tandon, Abhishek, Pandey, Latika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374827/ https://www.ncbi.nlm.nih.gov/pubmed/34146077 http://dx.doi.org/10.4103/ijo.IJO_1143_21 |
Ejemplares similares
-
What ophthalmologists should know about conjunctivitis in the COVID-19 pandemic?
por: Shetty, Rohit, et al.
Publicado: (2020) -
Should statins be considered for the management of mucormycosis in COVID-19?
por: Chatterjee, Subhankar, et al.
Publicado: (2021) -
COVID-19-Associated Mucormycosis: What Neurologists Should Know?
por: Kulkarni, Rahul, et al.
Publicado: (2022) -
COVID-19 Pandemic and Ophthalmologists
por: Beuy, Joob, et al.
Publicado: (2020) -
What All We Should Know About Masks in COVID-19 Pandemic
por: Agrawal, Himanshu, et al.
Publicado: (2020)